The U.S. is purchasing an additional 10 million courses of Paxlovid, Pfizer’s COVID-19 antiviral, the drugmaker said Jan. 4.
Read the full post on Becker's Hospital Review - Healthcare News
Read the full post on Becker's Hospital Review - Healthcare News